Table 1.

Association between clinicopathological variables and immunohistochemical results of p14ARF, p15INK4b, and p16INK4a

p14ARFp15INK4bp16INK4a
VariableNo. of patientsPreservedDecreasedPPreservedDecreasedPPreservedDecreasedP
Clinical variables (primary cases, n = 85)
 Age, y
  <504624220.9321250.9622240.58
  ≥5039201918212118
 Sex
  Male4526190.2422230.5620250.23
  Female40182217232317
 NF1
  Present3316170.6314190.6115180.45
  Absent52282425272824
 Site
  Extremity3820180.9817210.2919190.77
  Trunk wall201010128911
  Head and neck/   retroperitoneum/   visceral/spine27141310171512
 Tumor depth
  Superficial211290.571290.239120.41
  Deep64323227373430
 Tumor size
  <5cm241590.211680.0151590.17
  ≥5cm61293223382833
 Adjuvant therapy
  Given3030.11210.59211.00
  Not given82443837454141
 AJCC staging
  I2614120.2114120.6314120.81
  II41212016252219
  III14867768
  IV3031212
Pathological variables (all cases, n = 129)
 Tumor necrosis
  No necrosis6337260.3039240.1734290.28
  <50%52232924283121
  ≥50%14776859
 Mitotic counts
  0–9/10HPF8445390.1142420.4241430.11
  10–19/10HPF175129898
  ≥20/10HPF2817111810208
 Ki-67–labeling index
  0%–9%3120110.04313180.3317140.94
  10%–29%57322532253027
  ≥30%41152624172318
 Microvessel density
  <15/HPF6429350.1333310.6631330.19
  ≥15/HPF65382736293926
 Rhabdomyoblastic differentiation
  Present165110.074880.77790.37
  Absent113625161526350
 Epithelioid feature
  Present8260.11260.091440.80
  Absent121655667546655
 FNCLCC grading
  14125160.3726150.06620210.68
  259283125343326
  329141518111712